Literature DB >> 16783533

Patients' attitude to subcutaneous immunoglobulin substitution as home therapy.

J M Kittner1, B Grimbacher, W Wulff, B Jäger, R E Schmidt.   

Abstract

INTRODUCTION: Since 2003, immunoglobulin preparations have been approved for subcutaneous (s.c.) use in Germany. Although all our adult patients on intravenous (i.v.) substitution were offered to switch to s.c. home therapy, approximately half of them refused to change.
METHODS: To evaluate patients' attitude towards s.c. home therapy, a questionnaire was developed and sent to 125 patients. Questions had to be answered by ticking numbers on a Likert scale from 1 (not at all) to 8 (very much). Four scales of the Freiburg Personality Inventory (FPI) were added. From the 70 questionnaires returned (56%), 61 could be analysed (i.v. n = 28, s.c. n = 33).
RESULTS: The i.v. treated patients were afraid of being more busy with self-administration (6.9 +/- 2.1). This was not a serious concern in the s.c. treated group (3.6 +/- 1.8, p < 0.001). Many i.v. treated patients worried about severe adverse reactions at home (4.7 +/- 2.8), but patients in the s.c. group did not (1.7 +/- 1.0, p < 0.001). The statement "I dislike to puncture myself" reached 5.3 +/- 2.7 points in the i.v. treated group, but only 2.0 +/- 1.1 (p < 0.001) in the s.c. treated patients. As main reason, patients on i.v. substitution considered s.c. therapy as inconvenient (48%). Secondly, they were afraid of side effects (31%). All patients on s.c. therapy appreciated the new treatment (7.2 +/- 1.0). Main advantage for them was an increase of flexibility (6.6 +/- 1.6). The FPI displayed lower values for s.c. treated patients in the scales "Physical Complaints" and "Emotional Lability".
CONCLUSION: Those patients who had changed to s.c. therapy were highly satisfied. However, others preferred to stay on i.v. treatment for different reasons. Perception of inconvenience, anxiety of side effects, but also personal traits may play a role.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16783533     DOI: 10.1007/s10875-006-9031-5

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  11 in total

1.  Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy.

Authors:  U Nicolay; S Haag; F Eichmann; S Herget; D Spruck; A Gardulf
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

2.  Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion.

Authors:  A Gardulf; L Hammarström; C I Smith
Journal:  Lancet       Date:  1991-07-20       Impact factor: 79.321

3.  Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.

Authors:  Uwe Nicolay; Peter Kiessling; Melvin Berger; Sudhir Gupta; Leman Yel; Chaim M Roifman; Ann Gardulf; Florian Eichmann; Stefan Haag; Cordula Massion; Hans D Ochs
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

4.  The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Authors:  H M Chapel; G P Spickett; D Ericson; W Engl; M M Eibl; J Bjorkander
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

5.  The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions.

Authors:  A Gardulf; H Björvell; R Gustafson; L Hammarström; C I Smith
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

6.  Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency.

Authors:  A Gardulf; H Björvell; R Gustafson; L Hammarström; C I Smith
Journal:  Immunodeficiency       Date:  1993

7.  High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease.

Authors:  C M Roifman; H Levison; E W Gelfand
Journal:  Lancet       Date:  1987-05-09       Impact factor: 79.321

8.  Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.

Authors:  Ann Gardulf; Uwe Nicolay; Dipl Math; Oscar Asensio; Ewa Bernatowska; Andreas Böck; Beatriz T Costa-Carvalho; Carl Granert; Stefan Haag; Dolores Hernández; Peter Kiessling; Jan Kus; Nuria Matamoros; Tim Niehues; Sigune Schmidt; Ilka Schulze; Michael Borte
Journal:  J Allergy Clin Immunol       Date:  2004-10       Impact factor: 10.793

9.  Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance.

Authors:  Barbara Högy; Heinz-Otto Keinecke; Michael Borte
Journal:  Eur J Health Econ       Date:  2005-03

10.  Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy.

Authors:  A Gardulf; H Björvell; V Andersen; J Björkander; D Ericson; S S Frøland; R Gustafson; L Hammarström; T Nyström; B Søeberg
Journal:  J Adv Nurs       Date:  1995-05       Impact factor: 3.187

View more
  30 in total

1.  New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins.

Authors:  Martin Stangel
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

2.  9 Human Immunoglobulins.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 3.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors:  Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

4.  Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model.

Authors:  David W Kang; Laurence Jadin; Tara Nekoroski; Fred H Drake; Monica L Zepeda
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

Review 5.  Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.

Authors:  Richard L Wasserman
Journal:  J Clin Immunol       Date:  2012-07-25       Impact factor: 8.317

6.  Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.

Authors:  R L Wasserman; A-M Irani; J Tracy; C Tsoukas; D Stark; R Levy; J Chen; S Sorrells; R Roberts; S Gupta
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

7.  Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis.

Authors:  Ralph Shapiro
Journal:  J Clin Immunol       Date:  2010-01-15       Impact factor: 8.317

8.  Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies.

Authors:  R Gustafson; A Gardulf; S Hansen; H Leibl; W Engl; M Lindén; A Müller; L Hammarström
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

9.  Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.

Authors:  John B Hagan; Mary B Fasano; Sheldon Spector; Richard L Wasserman; Isaac Melamed; Mikhail A Rojavin; Othmar Zenker; Jordan S Orange
Journal:  J Clin Immunol       Date:  2010-05-08       Impact factor: 8.317

Review 10.  Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.

Authors:  Jenny Lingman-Framme; Anders Fasth
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.